Forst Rita, a director at AerCap Holdings N.V., has filed a Form 144 to sell 2,000 ordinary shares of the company. This sale is valued at approximately $310,960 based on the closing share price of $155.48 on October 28, 2026. The timing of this filing is significant as it follows the vesting of restricted stock granted to Rita under the company’s equity incentive plan.
AerCap Holdings N.V. operates in the equipment rental and leasing sector, which is characterized by ongoing adjustments as companies navigate market conditions. Rita's decision to sell shares may reflect broader trends within the industry, where executives frequently adjust their holdings.
Background
AerCap Holdings N.V. is a prominent player in the equipment rental and leasing industry. The company is incorporated in Dublin, Ireland, and is listed on the New York Stock Exchange under the SEC file number 001-33159. The company's address is Aercap House, 65 St. Stephen's Green, Dublin, L2, D02 YX20.
What the Filing Says
The filing indicates that Rita Forst acquired 10,400 ordinary shares on December 17, 2023, through the vesting of restricted stock. The filing notes, "Aggregate Market Value of shares calculated based on a closing share price of $155.48 on October 28, 2026." Forst has also sold 2,000 shares in the past three months, with gross proceeds of $311,280 from that sale.
Impact
This filing may impact AerCap's shareholders and potential investors as they assess the company's executive trading activities. Rita Forst's actions could influence market perceptions regarding the company's future performance and executive confidence in its stock.
What's Next
The filing does not say what happens next.
Read Next
Workers United Files to Sell $8.4 Million in Amalgamated Stock
Carvana Co. files to sell 10 million shares of stock
Platford Giles Richard to Sell 55,617 Takeda Shares
Takeda's Teresa Bitetti to Sell 46,609 Shares Amid Tax Obligations
Kiniksa Pharmaceuticals reports significant stock sale by officer
Moat Ross to Sell Over 103,000 Shares of Kiniksa Pharmaceuticals










